Genoa Pharma, McMaster U In IPF Research Pact

Genoa Pharmaceuticals and Dr. Martin Kolb and researchers at McMaster University have entered into a collaboration to characterize the in vivo advantages and potential clinical impact of Genoa’s lead program, inhaled GP-101 (aerosol pirfenidone) for the treatment of IPF. The research combines Genoa’s aerosol drug delivery expertise with McMaster’s expertise in exploring mechanisms of pulmonary fibrosis.
 
“Genoa is very excited about the opportunity to collaborate with Dr. Kolb and McMaster University to better understand how inhaled GP-101 may benefit IPF patients,” said Mark Surber, Ph.D., Genoa’s founder, president and chief scientific officer. “Genoa is committed to establishing academic relationships with leading institutions to further advance its efforts to develop novel treatments for IPF.”